Protein tyrosine kinases play a major role in promoting cell growth, and their activity in solid tumors is well established. Inhibitors of protein tyrosine kinases are now in advanced clinical trials for the treatment of breast and brain cancers. Because Src-related PTK have been shown to be activated in leukemic cell lines, we studied their activation in human myeloid leukemia. Blasts from the majority of patients with acute leukemia showed constitutive activity of the Src kinase Lyn. In contrast, no patient samples showed constitutive activation of Jak2. Genetic and pharmacologic targeting of Lyn was used to determine its contribution to leukemic cell growth. Antisense Lyn oligonucleotide treatment resulted in the inhibition of tritiated thymidine incorporation following GM-CSF stimulation of the factor-dependent line MO7e. The Src kinase inhibitor PD166285 inhibited the growth of human leukemic cell lines and leukemic blasts. When combined with doxorubicin, an additive effect on the inhibition of leukemic cell growth occurred. These studies demonstrate the importance of Src kinases in promoting leukemic cell growth and suggests that further development of agents which target Src kinases and their inclusion in multidrug regimens are warranted for novel therapies of myeloid leukemia.
Introduction
Although great improvements in clinical outcome have been achieved in childhood acute lymphoblastic leukemia, the same is not true for acute myelogenous leukemia (AML). AML occurs more frequently in adults. Despite intensive chemotherapy and bone marrow transplantation, long-term disease survival is no better than 65%. 1 In the elderly, AML typically follows a preleukemic syndrome, bone marrow transplantation is not a therapeutic option, and it is difficult to treat successfully. Greater understanding of myeloid leukemogenesis may lead to identification of the biochemical and genetic controls of myeloid cell proliferation and differentiation, as well as to the development of better therapeutics.
Hypothesizing that dysregulation of hematopoietic growth factor-induced proliferative signalling pathways contribute to leukemogenesis, we have been studying the immediate biochemical events following stimulation of factor-dependent hematopoietic cells by G-CSF and GM-CSF. By changing activation states of proteins or recruiting additional signalling molecules, protein tyrosine kinases (PTK) transduce signals that control cell proliferation and differentiation. One major family of PTK is related to the oncogene product, Src. 2 Evidence has accumulated from a variety of experimental approaches that the Src-related protein tyrosine kinase Lyn plays a critical role in mediating GM-CSF and G-CSF responses and myeloid leukemic cell proliferation. [3] [4] [5] [6] Having shown that the Lyn kinase is constitutively active in myeloid cell leukemia-derived cell lines, we found constitutive Lyn activity in primary leukemic blast cells from patients with AML. To determine the role of Lyn in promoting leukemic growth, we inhibited Lyn by antisense oligonucleotides, somatic cell gene targeting, and a novel Src kinase inhibitor. This compound, the tyrosine kinase kinase inhibitor, PD166285, is a member of a structural class, the 6-aryl-pyrido [2,3-d] pyrimidines, which has the attractive feature of oral bioavailability. PD166285 is most potent against Src-related protein tyrosine kinases, with an IC 50 of 8 nm. 7 Each of these therapeutic strategies resulted in inhibition of leukemic cell growth, with the most promising approach being pharmacologic. Thus, the addition of a tyrosine kinase inhibitor, which includes Src as a target, may improve outcome for patients with hematologic malignancies.
Materials and methods

Reagents
Recombinant human GM-CSF was a gift of Genetics Institute (Cambridge, MA, USA). Rabbit polyclonal antibodies were developed specifically to immunoprecipitate and immunoblot against Btk, Fyn, Lck, Lyn, Src, Syk, and ZAP-70 by Dr Joseph Bolen [8] [9] [10] [11] [12] and were used for the data presented in Figure 1a . Antibodies against Blk, Fyn Hck, Lck, and Lyn were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Jak2 and phosphotyrosine 4G10 were purchased from Upstate Biotechnology (Lake Placid, NY, USA). The Src inhibitor, PD166285 was a gift from Dr Alan Kraker of Parke-Davis (Ann Arbor, MI, USA). Wortmannin was purchased from Sigma (St Louis, MO, USA). AG490 was a kind gift of Dr Alex Levitzki (Hebrew University, Jerusalem, Israel) PD166285, wortmannin, and AG490 were dissolved in dimethyl sulfoxide (DMSO) and stored at −20°C prior to use.
Cell tissue
Primary leukemic blasts were isolated by Ficoll-Hypaque separation of bone marrow aspirates from newly diagnosed children with acute leukemia. Fresh myeloid blasts were obtained from diagnostic marrow aspirates of patients treated at Children's Hospital of Pittsburgh. Preparations were Ͼ95% viable leukemic blasts. Cryopreserved blast cells were obtained from Dr Irwin Bernstein at the Children's Cancer Group Myeloid Leukemia Repository (Fred C Hutchinson Cancer Center, Seattle, WA, USA). The human myeloid leukemia cell lines MO7e and TF-1 were grown in RPMI 1640 medium, supplemented with 10% fetal calf serum (Hyclone, Orham, UT, USA), 2 mm l-glutamine, 10 U/ml penicillin, 10 U/ml streptomycin (Life Technologies, Grand Island, NY, USA) and 10 ng/ml of recombinant human GM-CSF (provided by Genetics Institute) at 37°C with 5% CO 2 . The HL-60 cell line was grown in RPMI and 10% FCS, and the DT40 cell line was grown in RPMI supplemented with 10% FCS, and 2% chicken serum (Sigma).
In vitro protein kinase assay
Leukemia blasts were isolated by Ficoll-Hypaque separation, and lysed with detergent buffer (1% NP40, 137 mm NaCl, 20 mm Tris-HCl, pH 8, the protease inhibitors 1 mm EDTA, 1 mm PMSF, 10 g/ml aprotinin, 10 g/ml leupeptin, and the tyrosine phosphatase inhibitor 2 mm sodium orthovanadate). Post-nuclear supernatants were obtained by microcentrifugation and were standardized by assaying 400 g protein per immunoprecipitation. Immune complexes were washed three times with PBS/1% NP-40, twice with TNE (100 mm NaCl, 10 mm tris-Cl, 1 mm EDTA), and then incubated in 20 m of 2× TP buffer (10 mm MgCl 2 , 10 mm MnCl 2 , 40 mm Tris-Cl, 5 m ATP, and 10 Ci/sample ␥-32 P-ATP). After the 20-min reaction was stopped by the addition of 2× Laemmli buffer, the samples were boiled for 5 min and loaded on to a 7.5% polyacrylamide gel. The gel was fixed, dried and exposed to Dupont film for autoradiography. For the JAK2 activation assay, proteins immunoprecipitated with anti-Jak2 antibody and Staphylococcus protein A (Sigma) were washed three times with PBS/1%NP-40 and loaded on to a 7.5% SDS-PAGE. The gel was transferred on to PVDF filter paper and blotted with monoclonal antibody 4G10 to phosphotyrosine. Detection was by enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA).
Oligonucleotide treatment of MO7e cells
Nineteen base pair antisense and sense phosphorothioate (S-) oligodeoxynucleotides, which included the ATG translation start site of Lyn sequence, were synthesized and purified (Midland Certified Reagent, Midland, TX, USA). The antisense S-oligonucleotide sequence consisted of 5Ј-ATT TTA TAC ATC CCA TAT T-3Ј and the sense S-oligonucleotide sequence consisted of 5Ј-AAT ATG GGA TGT ATA AAA T-3Ј. MO7e cells were cultured in triplicate at 10 000 cells/well in flat bottom microtiter plates in the presence of 0.3 ng/ml GM-CSF. Multiple doses of the S-oligonucleotides were added at the indicated concentrations at 0, 18, and 24 h. The cultures were pulsed with 1 Ci 3 H-thymidine (NEN Dupont, Boston, MA, USA) for the last 4 h of culture. The plates were harvested on to glass fiber filters with a semi-automated cell harvester, 1 ml Cytoscint scintillation fluid (ICN Biomedical, Irvine, CA, USA) was added, and the samples were counted on a Beta counter (Packard, Downers Grove, IL, USA).
Src kinase inhibition of myeloid leukemic cell lines, blasts, and bone marrow cells
Bone marrow-derived blast cells from patients with AML or progenitor cells from healthy individuals were obtained by Ficoll-Hypaque separation. Mononuclear cells were plated in methylcellulose supplemented with GM-CSF, erythropoietin, stem cell factor, and IL-3 (Methocult, Stemcell Technologies, Vancouver, BC, Canada), with DMSO or PD166285 and colonies were counted at 17 days. Leukemic cells were also incubated in RPMI and 10% FCS with DMSO or PD166285, and short-term growth was measured.
Informed consent
Analysis of primary leukemic blasts was performed on residual patient samples. Informed consent for bone marrow examination was obtained, and permission to use residual tissue was given by Children's Hospital of Pittsburgh Institutional Review Board.
Results
Expression of Src kinase activity in primary leukemic blast cells
Constitutive protein tyrosine kinase activity was determined by immune complex kinase assay, either on fresh or cryopre- served samples. Kinase activity was determined by autophosphorylation, as exemplified in Figure 1a . We studied the Src kinases found predominantly in myeloid cells (Hck and Lyn) and compared them to those found predominantly in lymphoid tissues (Blk, Fyn, and Lck). The majority of patient samples demonstrated constitutive Lyn activity (Table 1) . Whenever Hck was activated, so was Lyn. In 4/14 patients, the lymphoid Src kinases Lck and Fyn were activated. Fyn was found to be activated in the presence of Lck. The FAB classification of these four patients were M1, M2, and M4. Four of the 20 patients studied showed no kinase activity, and the FAB classification comprised M1, M4, and M5. Due to sample size, statistical significance of constitutive kinase activity cannot be attributed to either prognosis or FAB classification. Because Jak2 plays a critical role in hematopoietic cell signalling, we studied Jak2 activation by phosphotyrosine blotting of Jak2 immunoprecipitated protein. Constitutive activation of Jak2 was found in none of the nine patients studied. However, when blast cells were obtained from the bone marrow aspirate of a patient with M2 AML, the blast cells showed activation of Jak2 following exposure to G-CSF (Figure 1b) . This indicates that functional Jak2 is present, but not constitutively active, in primary myeloid leukemia cells.
Lyn antisense treatment results in inhibition of GM-CSF-induced proliferation
To determine if Lyn played a role in promoting myeloid leukemic cell growth, we targeted Lyn by genetic and pharmacologic means. The expression and function of Lyn may be affected by treating cells with antisense oligonucleotides. 5, 13, 14 We therefore studied the effects of lyn antisense treatment on GM-CSF-induced proliferation. 19-mer antisense and sense phosphorothioate (S-) oligodeoxynucleotides, which included the ATG translation start site of lyn sequence, were synthesized and purified. Lyn kinase activity was inhibited by treatment with antisense, but not nonsense, oligonucleotides (Figure 2a) . Incubation of MO7e cells with a lyn antisense oligonucleotide resulted in a dose-dependent decrease in GM-CSF-induced proliferation (Figure 2b ). The apparent therapeutic window for lyn antisense S-oligonucleotide is narrow since greater than 2.5 m concentrations of either antisense or sense S-oligonucleotides resulted in poor mitogenic response. Although the toxic effects of the sense oligonucleotide develop at concentrations greater than 1.25 m, a difference of 30% inhibition remains at this concentration. To determine the efficacy of lyn antisense treatment in preventing Lyn protein synthesis, and hence kinase activity, MO7e cells were treated with 1.25 m S-oligonucleotides for 24 h, harvested, and assayed for Lyn activity. Densitometric analysis showed that lyn antisense treatment resulted in a 42 ± 10% decrease in kinase activity (data not shown). The lack of complete inhibition of lyn anti-
Figure 3
Dose-response of tyrosine kinase inhibitor PD166285 on Lyn autophosphorylation in TF-1, HL60 cells, and DT40. TF-1 and HL60 cells, which express multiple Src kinases, and DT40 cells, which express only Lyn, were treated during mid-log phase of growth with varying concentrations of PD166285 or DMSO (control diluent) for 1 h. Cells were then lysed, and immunoprecipitated Lyn was assayed for kinase activity. The gel was analyzed by Molecular Dynamics Phosphorimager, and % of control kinase activity was calculated. Results shown are the averages. sense on GM-CSF-induced proliferation of MO7e cells can at least be explained by its partial inhibition of protein expression. Unfortunately, at greater concentrations the toxicity of S-oligonucleotides obscured differences between antisense and sense treatment.
Pharmacologic inhibition of Lyn by PD166285
PD166285 is a novel protein tyrosine kinase inhibitor, one of the most potent analogs of the pyrido [2,3-d] pyrimidine class, which acts as an ATP competitive inhibitor. PD166285 inhibits Src activity in vitro with an IC 50 of 8 nm and receptorencoded tyrosine kinase (eg FGFR-1, EGFR, and PDGFR) activity in vitro with an IC 50 of 40-100 nm. 7 Its inhibition of PDGFR was long-lasting. As an inhibitor of an early signalling event, PD166285 also effects downstream biochemical events such as MAP kinase activity. PD166285 inhibited Lyn kinase activity in HL-60 and TF-1 cells with an IC 50 of 500 nm and 100 nm, respectively ( Figure 3) . In contrast to both HL60 and TF-1 cells, which express multiple Src kinases, the DT40 B cell line expresses only Lyn. Thus, DT40 is a unique cell line to study the effects of a single functioning Src kinase. 15 The IC 50 of Lyn kinase inhibition in DT40 cells was 100 nm. PD166285 was specific for Src kinase activity as there was no effect on cytokine-induced activation of Jak2 in any of the cell lines tested (data not shown).
PD166285 inhibition of myeloid leukemic cell lines and myeloid leukemic blasts
Varying concentrations of the Src kinase inhibitor PD166285 and/or doxorubicin were added to freshly split HL60 and TF-1 cells, and the number of viable cells were counted at 24 and 48 h. 50% growth inhibition occurred at approximately 5 m for both HL60 and TF-1 cells (Figure 4a and b) . Treatment of HL60 and TF-1 cells with AG490, a relatively specific inhibitor of Jak2, showed a 50% growth inhibition at 10 m and 100 m, respectively.
When both PD166285 and a low-dose of doxorubicin were added, an additive effect in growth inhibition was seen in both cell lines. The DT40 cells, which express a single Src kinase, were exquisitely sensitive to PD166285. No cells excluded trypan blue at 24 h at PD166285 concentrations of 1 or 10 m. The enhanced sensitivity to the Src kinase inhibitor in DT40 cells may be due to the lack of redundant Src kinases. This possibility is suggested from the ability of 1 m PD166285 to inhibit PI 3-kinase activity in DT40 cells but not in TF-1 and HL60 cells (data not shown). An additive effect on growth inhibition was seen in cells treated with 0.1 m PD166285 and the PI 3-kinase inhibitor wortmannin (Table  2) . G-CSF treatment of DT40 cells which express the human G-CSF receptor did not rescue the effects of the Src or PI 3-kinase inhibitors (data not shown).
Fresh leukemia cells were isolated from a diagnostic bone marrow aspirate from a patient with AML, M2 subtype. Cell population, comprising Ͼ95% blasts, were suspended in RPMI and 10% FCS and either PD166285, wortmannin, doxorubicin or both PD166285 and doxorubicin. While each agent resulted in a time-dependent decrease in viable cells, as compared to DMSO-treated control cells, the combination of PD166285 and doxorubicin resulted in no viable cells by 72 h (Figure 4c) .
To determine the effects on apoptosis, treated cells were stained with propidium iodine and analyzed for DNA content by flow cytometry. Both HL60 and TF-1 cells showed early apoptotic changes to PD166285 and wortmannin, which were greater than that observed in low-dose doxorubicin ( Table 3) .
Inhibition of hematopoietic colony growth
Mononuclear bone marrow cells from healthy bone marrow transplant donors were obtained by Ficoll-Hypaque separation. Varying concentrations of PD166285, wortmannin, or doxorubicin were added to the cultures at day 0. Colonies were then counted 17 days later. While there was a doseresponse inhibition by the Src kinase inhibitor on the growth of BFU-E and CFU-GM derived from bone marrow cells, no such effect was seen with the PI 3-kinase inhibitor ( Figure 5 ). Doxorubin at 0.2 g/ml completely inhibited growth of hematopoietic colonies. Of note, bone marrow cells cultured in liquid medium and 10% FCS and treated with PD166285 failed to generate fibroblasts (data not shown). Fibroblasts grew in both wortmannin and doxorubicin-treated cells. It is possible that one mechanism of action for the tyrosine kinase inhibitor is to block stromal growth. In contrast to the profound inhibition on in vitro methylcellulose colony growth by PD 166285, mice treated with PD166285 did not have hematologic toxicity (data not shown). 
Figure 5
Effects of inhibitors on hematopoietic colony growth. Mononuclear bone marrow cells were purified and placed in methylcellulose cultures with or without PD166285 (PD) (100 nm, 1 m, and 10 m), wortmannin (wort) (100 nm, 1 m, and 10 m), or doxorubicin (doxo) (0.02 g/ml and 0.2 g/ml). Colonies were counted on day 17. Data are presented as the means ± s.d.
Discussion
Leukemia may result from autocrine or paracrine production of hematopoietic growth factors, such as GM-CSF. The critical dependency of acute myeloid leukemias (AML) for GM-CSF has been suggested by either the requirement of exogenous GM-CSF for in vitro culture of AML cells or the aberrant production of either GM-CSF or IL-3 by leukemic cells. [16] [17] [18] [19] Leukemia may also result from mutation of the cytokine receptors. For example, a subset of patients with severe congenital neutropenia who develop myelodysplasia or AML have mutations in their G-CSF receptors. 20, 21 These mutations introduce a premature stop codon, which results in a receptor which triggers proliferative but not differentiative signalling cascades.
Cytokines, such as GM-CSF and G-CSF, typically stimulate rapid changes in intracellular tyrosine phosphoproteins. One important class of PTK is a family related to the oncogene vsrc. Several src-related PTK are found in myeloid cells: Fgr, Hck, and Lyn. We and others have reported that the GM-CSF or IL-3 increases the tyrosine kinase activity of Hck and GM-CSF, IL-3, and G-CSF increase the activity of Lyn in myeloidderived cells. [4] [5] [6] 22, 23 Constitutive Lyn activity has been found in several factor-independent myeloid cell lines. Myeloid cells transformed with BcrAbl demonstrated an association between BcrAbl and Lyn and greater Lyn activity, suggesting a possible role for Lyn in chronic myelogenous leukemia. 24 Here, we report that constitutive Lyn activity is found in leukemic blasts freshly purified from the bone marrow aspirates of newly diagnosed patients with leukemia.
Because new forms of anti-leukemic therapy can be based on targeting growth-promoting events, investigators have studied inhibitors of tyrosine kinases. The non-specific inhibitor genistein is highly effective in inhibiting leukemic cell growth. 25, 26 We have asked whether Lyn specifically contributes to G-CSF or GM-CSF-stimulated DNA synthesis. We introduced components of the human G-CSF receptor or GM-CSF receptor complex into a bursal lymphoma cell line and its mutagenized, lyn-deficient form. G-CSF and GM-CSF induced DNA synthesis was found only when the G-CSF or GM-CSF receptors were expressed in the cell line which contains Lyn (Ref. 15 and unpublished observations, SM Anderson and SJ Corey). In a complementary approach, we treated the GM-CSF-dependent cell line MO7e with antisense oligonucleotides to Lyn and observed a dose-dependent inhibition of GM-CSF-induced growth.
These experiments demonstrate that PTK contribute significantly to leukemic cell growth and suggest that therapy directed against Src kinases, such as Lyn, may be effective in inhibiting myeloid cell growth. Because the activation of Lyn occurs rapidly and proximal to growth factor receptor engagement, it activates downstream PTK such as Syk and Btk (a member of the Tec family of PTK). Lyn is also associated with other important growth-promoting signalling molecules such as PI 3-kinase, Cbl, and cdc2. [27] [28] [29] [30] While Lyn appears to be most relevant Src-related PTK in myeloid cells, other Src kinases such as Hck or Fyn participate in myeloid cell signalling. 31 Selective inhibition of Src-related PTK may offer a highly effective, but less toxic addition to the treatment of myeloid leukemias. Furthermore, these studies should prompt the development of agents which inhibit Pl 3-kinase activity.
